MDGL Madrigal Pharmaceuticals, Inc.

NASDAQ
$421.99

Madrigal Pharmaceuticals, Inc. (MDGL) Earnings News

Earnings press releases, previews and reviews for Madrigal Pharmaceuticals, Inc. (MDGL), newest first. Our most recent is review: Madrigal Turns Its First Profit on Rezdiffra Strength, but Slowing Growth Rates and 2027 Pricing Pressure Keep the Debate Alive.